Lynparza nearly doubled time patients lived with
Lynparza nearly doubled the time patients lived without disease progression from germline BRCA-mutated metastatic pancreatic cancer 22% of patients receiving Lynparza remained free ofdisease progression after two years vs. 10% on placebo Lynparza now the first PARP inhibitor todemonstrate benefit in three different cancer types 3 June 2019 07:00 BST AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced detailed results from the Phase III POLO trial at the 2019 American Society of Clinical Oncology (ASCO)